Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6P1A2
UPID:
MBOA5_HUMAN
Alternative names:
1-acylglycerophosphocholine O-acyltransferase; 1-acylglycerophosphoethanolamine O-acyltransferase; 1-acylglycerophosphoserine O-acyltransferase; Lysophosphatidylcholine acyltransferase; Lysophosphatidylcholine acyltransferase 3; Lysophosphatidylserine acyltransferase; Membrane-bound O-acyltransferase domain-containing protein 5
Alternative UPACC:
Q6P1A2; B2RDH0; B7Z3N3; Q7KZS1; Q92980; Q9BW40
Background:
Lysophospholipid acyltransferase 5, known by alternative names such as 1-acylglycerophosphocholine O-acyltransferase and Lysophosphatidylcholine acyltransferase 3, plays a pivotal role in the phospholipid remodeling process, also known as the Lands cycle. It catalyzes the transfer of fatty acyl chains to lysophospholipids, forming various phospholipids essential for cellular functions. This enzyme exhibits a preference for polyunsaturated fatty acyl-CoAs and is a major LPC O-acyltransferase in liver and intestine, involved in processes such as VLDL particle formation and the regulation of lipid-induced ER stress response.
Therapeutic significance:
Understanding the role of Lysophospholipid acyltransferase 5 could open doors to potential therapeutic strategies.